Prepulse Inhibition of Startle in Cocaine Dependence - 7 - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

April 18, 2001

Last Updated Date

November 3, 2005

Start Date ^†

February 1997

Current Primary Outcome Measures ^†

Percent prepulse inhibition
Cocaine assessment

Original Primary Outcome Measures ^†

Same as current

Change History

Complete list of historical versions of study NCT00015249 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

Original Secondary Outcome Measures ^†

Descriptive Information

Brief Title ^†

Prepulse Inhibition of Startle in Cocaine Dependence - 7

Official Title ^†

Prepulse Inhibition of Startle in Cocaine Dependence (Human)

Brief Summary

The purpose of this study is to assess the effects of chronic cocaine use on the acoustic startle response and on gating of this response in humans.

Detailed Description

The objective of this study is to assess the effects of chronic cocaine use on the acoustic startle response and on gating of this response in humans.

Study Phase

Phase I

Study Type ^†

Interventional

Study Design ^†

Diagnostic, Double-Blind, Placebo Control

Condition ^†

Cocaine-Related Disorders
Substance-Related Disorders

Intervention ^†

Drug: Amantadine

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Completed

Enrollment ^†

Completion Date

Primary Completion Date

Eligibility Criteria ^†

Inclusion Criteria:

Cocaine dependence. Male. Right handed. Negative urine for cocaine

Exclusion Criteria:

Positive urine for cocaine. History of head trauma. Significant medical disease.

Gender

Male

Ages

18 Years to 60 Years

Accepts Healthy Volunteers

Contacts ^††

Location Countries ^†

United States

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00015249

Responsible Party

Secondary IDs ^††

Y01-5-0013-7

Study Sponsor ^†

National Institute on Drug Abuse (NIDA)

Collaborators ^††

New York MDRU

Investigators ^†

Principal Investigator:

John Rotrosen, M.D.

New York MDRU

Information Provided By

National Institute on Drug Abuse (NIDA)

Verification Date

June 1998

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.